APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antinematode Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antinematode Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025196 pages

Choose your research edition.

Industry ResearchAntinematode Drugs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Antinematode Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Antinematode Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antinematode Drugs Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Antinematode Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Antinematode Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antinematode Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antinematode Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antinematode Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antinematode Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antinematode Drugs include Zhejiang Anbet Pharmaceutical Co., Ltd., Sichuan Tiande Pharmaceutical Co., Ltd., Shaoxing Minsheng Pharmaceutical Co., Ltd., Shanghai Tengrui Pharmaceutical Co., Ltd., Shanghai SPH Xinyi Pharmaceutical Co., Ltd., Shaanxi Hanwang Pharmaceutical Co., Ltd., Jiaozuo Furuitang Pharmaceutical Co., Ltd., China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. and Hubei Ruihua Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antinematode Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antinematode Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antinematode Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antinematode Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Antinematode Drugs Segment by Company

Zhejiang Anbet Pharmaceutical Co., Ltd.

Sichuan Tiande Pharmaceutical Co., Ltd.

Shaoxing Minsheng Pharmaceutical Co., Ltd.

Shanghai Tengrui Pharmaceutical Co., Ltd.

Shanghai SPH Xinyi Pharmaceutical Co., Ltd.

Shaanxi Hanwang Pharmaceutical Co., Ltd.

Jiaozuo Furuitang Pharmaceutical Co., Ltd.

China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd.

Hubei Ruihua Pharmaceutical Co., Ltd.

Guilin Nanyao Pharmaceutical Co., Ltd.

Fujian Dongrui Pharmaceutical Co., Ltd.

Diao Group Chengdu Pharmaceutical Co., Ltd.

Chengdu Hengda Pharmaceutical Co., Ltd.

Beijing Taiyang Pharmaceutical Co., Ltd.

Anhui Shengying Pharmaceutical Co., Ltd.

Sequent Scientific

Salius Pharma

Lasa Supergenerics Limited

K.A. Malle Pharmaceuticals

Johnson & Johnson

GlaxoSmithKline

Fredun Pharmaceuticals Ltd

Esteve Pharmaceuticals

Eipico

Cadila Pharmaceuticals

Amneal Pharmaceuticals

Antinematode Drugs Segment by Type

Albendazole

Mebendazole

Piperazine

Pyrantel Pamoate

Others

Antinematode Drugs Segment by Application

For Veterinary Use

For Human Use

Antinematode Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antinematode Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antinematode Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antinematode Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antinematode Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antinematode Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antinematode Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antinematode Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antinematode Drugs Industry Trends Table 2. Antinematode Drugs Industry Drivers Table 3. Antinematode Drugs Industry Opportunities and Challenges Table 4. Antinematode Drugs Industry Restraints Table 5. Global Antinematode Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antinematode Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antinematode Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Antinematode Drugs Sales Market Share by Manufacturers Table 9. Global Antinematode Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Antinematode Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antinematode Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antinematode Drugs Manufacturers, Product Type & Application Table 13. Global Antinematode Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antinematode Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Albendazole Table 17. Major Manufacturers of Mebendazole Table 18. Major Manufacturers of Piperazine Table 19. Major Manufacturers of Pyrantel Pamoate Table 20. Major Manufacturers of Others Table 21. Global Antinematode Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Antinematode Drugs Sales by Type (2021-2026) & (K Units) Table 23. Global Antinematode Drugs Sales by Type (2027-2032) & (K Units) Table 24. Global Antinematode Drugs Sales Market Share by Type (2021-2026) Table 25. Global Antinematode Drugs Sales Market Share by Type (2027-2032) Table 26. Global Antinematode Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Antinematode Drugs Revenue by Type (2021-2026) & (K Units) Table 28. Global Antinematode Drugs Revenue by Type (2027-2032) & (K Units) Table 29. Global Antinematode Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Antinematode Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of For Veterinary Use Table 32. Major Manufacturers of For Human Use Table 33. Global Antinematode Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Antinematode Drugs Sales by Application (2021-2026) & (K Units) Table 35. Global Antinematode Drugs Sales by Application (2027-2032) & (K Units) Table 36. Global Antinematode Drugs Sales Market Share by Application (2021-2026) Table 37. Global Antinematode Drugs Sales Market Share by Application (2027-2032) Table 38. Global Antinematode Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Antinematode Drugs Revenue by Application (2021-2026) & (K Units) Table 40. Global Antinematode Drugs Revenue by Application (2027-2032) & (K Units) Table 41. Global Antinematode Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Antinematode Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Antinematode Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Antinematode Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Antinematode Drugs Sales Market Share by Region (2021-2026) Table 46. Global Antinematode Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Antinematode Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Antinematode Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 50. North America Antinematode Drugs Sales by Country (2027-2032) & (K Units) Table 51. Europe Antinematode Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 53. Europe Antinematode Drugs Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Antinematode Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Antinematode Drugs Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Antinematode Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Antinematode Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Antinematode Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Antinematode Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Antinematode Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Antinematode Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Antinematode Drugs Revenue Market Share by Region (2027-2032) Table 65. Zhejiang Anbet Pharmaceutical Co., Ltd. Company Information Table 66. Zhejiang Anbet Pharmaceutical Co., Ltd. Business Overview Table 67. Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 69. Zhejiang Anbet Pharmaceutical Co., Ltd. Recent Development Table 70. Sichuan Tiande Pharmaceutical Co., Ltd. Company Information Table 71. Sichuan Tiande Pharmaceutical Co., Ltd. Business Overview Table 72. Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 74. Sichuan Tiande Pharmaceutical Co., Ltd. Recent Development Table 75. Shaoxing Minsheng Pharmaceutical Co., Ltd. Company Information Table 76. Shaoxing Minsheng Pharmaceutical Co., Ltd. Business Overview Table 77. Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 79. Shaoxing Minsheng Pharmaceutical Co., Ltd. Recent Development Table 80. Shanghai Tengrui Pharmaceutical Co., Ltd. Company Information Table 81. Shanghai Tengrui Pharmaceutical Co., Ltd. Business Overview Table 82. Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 84. Shanghai Tengrui Pharmaceutical Co., Ltd. Recent Development Table 85. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Company Information Table 86. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Business Overview Table 87. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 89. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Recent Development Table 90. Shaanxi Hanwang Pharmaceutical Co., Ltd. Company Information Table 91. Shaanxi Hanwang Pharmaceutical Co., Ltd. Business Overview Table 92. Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 94. Shaanxi Hanwang Pharmaceutical Co., Ltd. Recent Development Table 95. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Company Information Table 96. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Business Overview Table 97. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 99. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Recent Development Table 100. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Company Information Table 101. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Business Overview Table 102. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 104. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Recent Development Table 105. Hubei Ruihua Pharmaceutical Co., Ltd. Company Information Table 106. Hubei Ruihua Pharmaceutical Co., Ltd. Business Overview Table 107. Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 109. Hubei Ruihua Pharmaceutical Co., Ltd. Recent Development Table 110. Guilin Nanyao Pharmaceutical Co., Ltd. Company Information Table 111. Guilin Nanyao Pharmaceutical Co., Ltd. Business Overview Table 112. Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 114. Guilin Nanyao Pharmaceutical Co., Ltd. Recent Development Table 115. Fujian Dongrui Pharmaceutical Co., Ltd. Company Information Table 116. Fujian Dongrui Pharmaceutical Co., Ltd. Business Overview Table 117. Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 119. Fujian Dongrui Pharmaceutical Co., Ltd. Recent Development Table 120. Diao Group Chengdu Pharmaceutical Co., Ltd. Company Information Table 121. Diao Group Chengdu Pharmaceutical Co., Ltd. Business Overview Table 122. Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 124. Diao Group Chengdu Pharmaceutical Co., Ltd. Recent Development Table 125. Chengdu Hengda Pharmaceutical Co., Ltd. Company Information Table 126. Chengdu Hengda Pharmaceutical Co., Ltd. Business Overview Table 127. Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 129. Chengdu Hengda Pharmaceutical Co., Ltd. Recent Development Table 130. Beijing Taiyang Pharmaceutical Co., Ltd. Company Information Table 131. Beijing Taiyang Pharmaceutical Co., Ltd. Business Overview Table 132. Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 134. Beijing Taiyang Pharmaceutical Co., Ltd. Recent Development Table 135. Anhui Shengying Pharmaceutical Co., Ltd. Company Information Table 136. Anhui Shengying Pharmaceutical Co., Ltd. Business Overview Table 137. Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 139. Anhui Shengying Pharmaceutical Co., Ltd. Recent Development Table 140. Sequent Scientific Company Information Table 141. Sequent Scientific Business Overview Table 142. Sequent Scientific Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Sequent Scientific Antinematode Drugs Product Portfolio Table 144. Sequent Scientific Recent Development Table 145. Salius Pharma Company Information Table 146. Salius Pharma Business Overview Table 147. Salius Pharma Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Salius Pharma Antinematode Drugs Product Portfolio Table 149. Salius Pharma Recent Development Table 150. Lasa Supergenerics Limited Company Information Table 151. Lasa Supergenerics Limited Business Overview Table 152. Lasa Supergenerics Limited Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Lasa Supergenerics Limited Antinematode Drugs Product Portfolio Table 154. Lasa Supergenerics Limited Recent Development Table 155. K.A. Malle Pharmaceuticals Company Information Table 156. K.A. Malle Pharmaceuticals Business Overview Table 157. K.A. Malle Pharmaceuticals Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. K.A. Malle Pharmaceuticals Antinematode Drugs Product Portfolio Table 159. K.A. Malle Pharmaceuticals Recent Development Table 160. Johnson & Johnson Company Information Table 161. Johnson & Johnson Business Overview Table 162. Johnson & Johnson Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. Johnson & Johnson Antinematode Drugs Product Portfolio Table 164. Johnson & Johnson Recent Development Table 165. GlaxoSmithKline Company Information Table 166. GlaxoSmithKline Business Overview Table 167. GlaxoSmithKline Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 168. GlaxoSmithKline Antinematode Drugs Product Portfolio Table 169. GlaxoSmithKline Recent Development Table 170. Fredun Pharmaceuticals Ltd Company Information Table 171. Fredun Pharmaceuticals Ltd Business Overview Table 172. Fredun Pharmaceuticals Ltd Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 173. Fredun Pharmaceuticals Ltd Antinematode Drugs Product Portfolio Table 174. Fredun Pharmaceuticals Ltd Recent Development Table 175. Esteve Pharmaceuticals Company Information Table 176. Esteve Pharmaceuticals Business Overview Table 177. Esteve Pharmaceuticals Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 178. Esteve Pharmaceuticals Antinematode Drugs Product Portfolio Table 179. Esteve Pharmaceuticals Recent Development Table 180. Eipico Company Information Table 181. Eipico Business Overview Table 182. Eipico Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 183. Eipico Antinematode Drugs Product Portfolio Table 184. Eipico Recent Development Table 185. Cadila Pharmaceuticals Company Information Table 186. Cadila Pharmaceuticals Business Overview Table 187. Cadila Pharmaceuticals Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 188. Cadila Pharmaceuticals Antinematode Drugs Product Portfolio Table 189. Cadila Pharmaceuticals Recent Development Table 190. Amneal Pharmaceuticals Company Information Table 191. Amneal Pharmaceuticals Business Overview Table 192. Amneal Pharmaceuticals Antinematode Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 193. Amneal Pharmaceuticals Antinematode Drugs Product Portfolio Table 194. Amneal Pharmaceuticals Recent Development Table 195. Key Raw Materials Table 196. Raw Materials Key Suppliers Table 197. Antinematode Drugs Distributors List Table 198. Antinematode Drugs Customers List Table 199. Research Programs/Design for This Report Table 200. Authors List of This Report Table 201. Secondary Sources Table 202. Primary Sources List of Figures Figure 1. Antinematode Drugs Product Image Figure 2. Global Antinematode Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antinematode Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Antinematode Drugs Sales (2021-2032) & (K Units) Figure 5. Global Antinematode Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antinematode Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Albendazole Image Figure 9. Mebendazole Image Figure 10. Piperazine Image Figure 11. Pyrantel Pamoate Image Figure 12. Others Image Figure 13. Global Antinematode Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Antinematode Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Antinematode Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Antinematode Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Antinematode Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Antinematode Drugs Revenue Market Share by Type (2021-2032) Figure 19. For Veterinary Use Image Figure 20. For Human Use Image Figure 21. Global Antinematode Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Antinematode Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Antinematode Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Antinematode Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Antinematode Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Antinematode Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Antinematode Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Antinematode Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Antinematode Drugs Sales Market Share by Country (2021-2032) Figure 41. China Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Antinematode Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Antinematode Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Antinematode Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Antinematode Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Antinematode Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Antinematode Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Antinematode Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Antinematode Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Antinematode Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Antinematode Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Antinematode Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Antinematode Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Antinematode Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Antinematode Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Albendazole
  • Mebendazole
  • Piperazine
  • Pyrantel Pamoate
  • Others
Applications
  • For Veterinary Use
  • For Human Use
Companies covered
  • Zhejiang Anbet Pharmaceutical Co., Ltd.
  • Sichuan Tiande Pharmaceutical Co., Ltd.
  • Shaoxing Minsheng Pharmaceutical Co., Ltd.
  • Shanghai Tengrui Pharmaceutical Co., Ltd.
  • Shanghai SPH Xinyi Pharmaceutical Co., Ltd.
  • Shaanxi Hanwang Pharmaceutical Co., Ltd.
  • Jiaozuo Furuitang Pharmaceutical Co., Ltd.
  • China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd.
  • Hubei Ruihua Pharmaceutical Co., Ltd.
  • Guilin Nanyao Pharmaceutical Co., Ltd.
  • Fujian Dongrui Pharmaceutical Co., Ltd.
  • Diao Group Chengdu Pharmaceutical Co., Ltd.
  • Chengdu Hengda Pharmaceutical Co., Ltd.
  • Beijing Taiyang Pharmaceutical Co., Ltd.
  • Anhui Shengying Pharmaceutical Co., Ltd.
  • Sequent Scientific
  • Salius Pharma
  • Lasa Supergenerics Limited
  • K.A. Malle Pharmaceuticals
  • Johnson & Johnson
  • GlaxoSmithKline
  • Fredun Pharmaceuticals Ltd
  • Esteve Pharmaceuticals
  • Eipico
  • Cadila Pharmaceuticals
  • Amneal Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antinematode Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antinematode Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antinematode Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antinematode Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antinematode Drugs Market Dynamics
  1. 2.1 Antinematode Drugs Industry Trends
  2. 2.2 Antinematode Drugs Industry Drivers
  3. 2.3 Antinematode Drugs Industry Opportunities and Challenges
  4. 2.4 Antinematode Drugs Industry Restraints
3 Antinematode Drugs Market by Manufacturers
  1. 3.1 Global Antinematode Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antinematode Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antinematode Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antinematode Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antinematode Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antinematode Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Antinematode Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antinematode Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antinematode Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antinematode Drugs Tier 1, Tier 2, and Tier 3
4 Antinematode Drugs Market by Type
  1. 4.1 Antinematode Drugs Type Introduction
  2. 4.1.1 Albendazole
  3. 4.1.2 Mebendazole
  4. 4.1.3 Piperazine
  5. 4.1.4 Pyrantel Pamoate
  6. 4.1.5 Others
  7. 4.2 Global Antinematode Drugs Sales by Type
  8. 4.2.1 Global Antinematode Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Antinematode Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Antinematode Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Antinematode Drugs Revenue by Type
  12. 4.3.1 Global Antinematode Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Antinematode Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Antinematode Drugs Revenue Market Share by Type (2021-2032)
5 Antinematode Drugs Market by Application
  1. 5.1 Antinematode Drugs Application Introduction
  2. 5.1.1 For Veterinary Use
  3. 5.1.2 For Human Use
  4. 5.2 Global Antinematode Drugs Sales by Application
  5. 5.2.1 Global Antinematode Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antinematode Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global Antinematode Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global Antinematode Drugs Revenue by Application
  9. 5.3.1 Global Antinematode Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Antinematode Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global Antinematode Drugs Revenue Market Share by Application (2021-2032)
6 Global Antinematode Drugs Sales by Region
  1. 6.1 Global Antinematode Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antinematode Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Antinematode Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Antinematode Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antinematode Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antinematode Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antinematode Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antinematode Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antinematode Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antinematode Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antinematode Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antinematode Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antinematode Drugs Revenue by Region
  1. 7.1 Global Antinematode Drugs Revenue by Region
  2. 7.1.1 Global Antinematode Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antinematode Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Antinematode Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Antinematode Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antinematode Drugs Revenue (2021-2032)
  8. 7.2.2 North America Antinematode Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antinematode Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Antinematode Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antinematode Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antinematode Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antinematode Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antinematode Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhejiang Anbet Pharmaceutical Co., Ltd.
  2. 8.1.1 Zhejiang Anbet Pharmaceutical Co., Ltd. Company Information
  3. 8.1.2 Zhejiang Anbet Pharmaceutical Co., Ltd. Business Overview
  4. 8.1.3 Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  6. 8.1.5 Zhejiang Anbet Pharmaceutical Co., Ltd. Recent Developments
  7. 8.2 Sichuan Tiande Pharmaceutical Co., Ltd.
  8. 8.2.1 Sichuan Tiande Pharmaceutical Co., Ltd. Company Information
  9. 8.2.2 Sichuan Tiande Pharmaceutical Co., Ltd. Business Overview
  10. 8.2.3 Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  12. 8.2.5 Sichuan Tiande Pharmaceutical Co., Ltd. Recent Developments
  13. 8.3 Shaoxing Minsheng Pharmaceutical Co., Ltd.
  14. 8.3.1 Shaoxing Minsheng Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Shaoxing Minsheng Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  18. 8.3.5 Shaoxing Minsheng Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Shanghai Tengrui Pharmaceutical Co., Ltd.
  20. 8.4.1 Shanghai Tengrui Pharmaceutical Co., Ltd. Company Information
  21. 8.4.2 Shanghai Tengrui Pharmaceutical Co., Ltd. Business Overview
  22. 8.4.3 Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  24. 8.4.5 Shanghai Tengrui Pharmaceutical Co., Ltd. Recent Developments
  25. 8.5 Shanghai SPH Xinyi Pharmaceutical Co., Ltd.
  26. 8.5.1 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Company Information
  27. 8.5.2 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Business Overview
  28. 8.5.3 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  30. 8.5.5 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Recent Developments
  31. 8.6 Shaanxi Hanwang Pharmaceutical Co., Ltd.
  32. 8.6.1 Shaanxi Hanwang Pharmaceutical Co., Ltd. Company Information
  33. 8.6.2 Shaanxi Hanwang Pharmaceutical Co., Ltd. Business Overview
  34. 8.6.3 Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  36. 8.6.5 Shaanxi Hanwang Pharmaceutical Co., Ltd. Recent Developments
  37. 8.7 Jiaozuo Furuitang Pharmaceutical Co., Ltd.
  38. 8.7.1 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Company Information
  39. 8.7.2 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Business Overview
  40. 8.7.3 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  42. 8.7.5 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Recent Developments
  43. 8.8 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd.
  44. 8.8.1 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  48. 8.8.5 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Hubei Ruihua Pharmaceutical Co., Ltd.
  50. 8.9.1 Hubei Ruihua Pharmaceutical Co., Ltd. Company Information
  51. 8.9.2 Hubei Ruihua Pharmaceutical Co., Ltd. Business Overview
  52. 8.9.3 Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  54. 8.9.5 Hubei Ruihua Pharmaceutical Co., Ltd. Recent Developments
  55. 8.10 Guilin Nanyao Pharmaceutical Co., Ltd.
  56. 8.10.1 Guilin Nanyao Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Guilin Nanyao Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  60. 8.10.5 Guilin Nanyao Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Fujian Dongrui Pharmaceutical Co., Ltd.
  62. 8.11.1 Fujian Dongrui Pharmaceutical Co., Ltd. Company Information
  63. 8.11.2 Fujian Dongrui Pharmaceutical Co., Ltd. Business Overview
  64. 8.11.3 Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  66. 8.11.5 Fujian Dongrui Pharmaceutical Co., Ltd. Recent Developments
  67. 8.12 Diao Group Chengdu Pharmaceutical Co., Ltd.
  68. 8.12.1 Diao Group Chengdu Pharmaceutical Co., Ltd. Company Information
  69. 8.12.2 Diao Group Chengdu Pharmaceutical Co., Ltd. Business Overview
  70. 8.12.3 Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  72. 8.12.5 Diao Group Chengdu Pharmaceutical Co., Ltd. Recent Developments
  73. 8.13 Chengdu Hengda Pharmaceutical Co., Ltd.
  74. 8.13.1 Chengdu Hengda Pharmaceutical Co., Ltd. Company Information
  75. 8.13.2 Chengdu Hengda Pharmaceutical Co., Ltd. Business Overview
  76. 8.13.3 Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  78. 8.13.5 Chengdu Hengda Pharmaceutical Co., Ltd. Recent Developments
  79. 8.14 Beijing Taiyang Pharmaceutical Co., Ltd.
  80. 8.14.1 Beijing Taiyang Pharmaceutical Co., Ltd. Company Information
  81. 8.14.2 Beijing Taiyang Pharmaceutical Co., Ltd. Business Overview
  82. 8.14.3 Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  84. 8.14.5 Beijing Taiyang Pharmaceutical Co., Ltd. Recent Developments
  85. 8.15 Anhui Shengying Pharmaceutical Co., Ltd.
  86. 8.15.1 Anhui Shengying Pharmaceutical Co., Ltd. Company Information
  87. 8.15.2 Anhui Shengying Pharmaceutical Co., Ltd. Business Overview
  88. 8.15.3 Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  90. 8.15.5 Anhui Shengying Pharmaceutical Co., Ltd. Recent Developments
  91. 8.16 Sequent Scientific
  92. 8.16.1 Sequent Scientific Company Information
  93. 8.16.2 Sequent Scientific Business Overview
  94. 8.16.3 Sequent Scientific Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Sequent Scientific Antinematode Drugs Product Portfolio
  96. 8.16.5 Sequent Scientific Recent Developments
  97. 8.17 Salius Pharma
  98. 8.17.1 Salius Pharma Company Information
  99. 8.17.2 Salius Pharma Business Overview
  100. 8.17.3 Salius Pharma Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Salius Pharma Antinematode Drugs Product Portfolio
  102. 8.17.5 Salius Pharma Recent Developments
  103. 8.18 Lasa Supergenerics Limited
  104. 8.18.1 Lasa Supergenerics Limited Company Information
  105. 8.18.2 Lasa Supergenerics Limited Business Overview
  106. 8.18.3 Lasa Supergenerics Limited Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Lasa Supergenerics Limited Antinematode Drugs Product Portfolio
  108. 8.18.5 Lasa Supergenerics Limited Recent Developments
  109. 8.19 K.A. Malle Pharmaceuticals
  110. 8.19.1 K.A. Malle Pharmaceuticals Company Information
  111. 8.19.2 K.A. Malle Pharmaceuticals Business Overview
  112. 8.19.3 K.A. Malle Pharmaceuticals Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 K.A. Malle Pharmaceuticals Antinematode Drugs Product Portfolio
  114. 8.19.5 K.A. Malle Pharmaceuticals Recent Developments
  115. 8.20 Johnson & Johnson
  116. 8.20.1 Johnson & Johnson Company Information
  117. 8.20.2 Johnson & Johnson Business Overview
  118. 8.20.3 Johnson & Johnson Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Johnson & Johnson Antinematode Drugs Product Portfolio
  120. 8.20.5 Johnson & Johnson Recent Developments
  121. 8.21 GlaxoSmithKline
  122. 8.21.1 GlaxoSmithKline Company Information
  123. 8.21.2 GlaxoSmithKline Business Overview
  124. 8.21.3 GlaxoSmithKline Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 GlaxoSmithKline Antinematode Drugs Product Portfolio
  126. 8.21.5 GlaxoSmithKline Recent Developments
  127. 8.22 Fredun Pharmaceuticals Ltd
  128. 8.22.1 Fredun Pharmaceuticals Ltd Company Information
  129. 8.22.2 Fredun Pharmaceuticals Ltd Business Overview
  130. 8.22.3 Fredun Pharmaceuticals Ltd Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Fredun Pharmaceuticals Ltd Antinematode Drugs Product Portfolio
  132. 8.22.5 Fredun Pharmaceuticals Ltd Recent Developments
  133. 8.23 Esteve Pharmaceuticals
  134. 8.23.1 Esteve Pharmaceuticals Company Information
  135. 8.23.2 Esteve Pharmaceuticals Business Overview
  136. 8.23.3 Esteve Pharmaceuticals Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Esteve Pharmaceuticals Antinematode Drugs Product Portfolio
  138. 8.23.5 Esteve Pharmaceuticals Recent Developments
  139. 8.24 Eipico
  140. 8.24.1 Eipico Company Information
  141. 8.24.2 Eipico Business Overview
  142. 8.24.3 Eipico Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Eipico Antinematode Drugs Product Portfolio
  144. 8.24.5 Eipico Recent Developments
  145. 8.25 Cadila Pharmaceuticals
  146. 8.25.1 Cadila Pharmaceuticals Company Information
  147. 8.25.2 Cadila Pharmaceuticals Business Overview
  148. 8.25.3 Cadila Pharmaceuticals Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Cadila Pharmaceuticals Antinematode Drugs Product Portfolio
  150. 8.25.5 Cadila Pharmaceuticals Recent Developments
  151. 8.26 Amneal Pharmaceuticals
  152. 8.26.1 Amneal Pharmaceuticals Company Information
  153. 8.26.2 Amneal Pharmaceuticals Business Overview
  154. 8.26.3 Amneal Pharmaceuticals Antinematode Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Amneal Pharmaceuticals Antinematode Drugs Product Portfolio
  156. 8.26.5 Amneal Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antinematode Drugs Value Chain Analysis
  2. 9.1.1 Antinematode Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antinematode Drugs Production Mode & Process
  6. 9.2 Antinematode Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antinematode Drugs Distributors
  9. 9.2.3 Antinematode Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst